188 Re-羟乙基二膦酸与帕米膦酸二钠联合治疗乳腺癌骨转移的临床价值

目的探讨188Re-羟乙基二膦酸(188Re-HEDP)联合帕米膦酸二钠治疗乳腺癌骨转移的临床价值.方法48例乳腺癌多发骨转移患者随机分为3组,分别接受188Re-HEDP、帕米膦酸二钠的单独治疗及两者的联合治疗.结果188Re-HEDP组、帕米膦酸二钠组、联合治疗组止痛有效率分别为73.3%、80.0%和100.0%;骨转移病灶控制有效率分别为40.0%、33.3%和66.7%.联合治疗组疗效明显高于188Re-HEDP组和帕米膦酸二钠组(P均＜0.05),而188Re-HEDP组与帕米膦酸二钠组间差异无统计学意义(P＞0.05).结论188Re-HEDP联合帕米膦酸二钠治疗乳腺癌骨转移,在止痛、骨转移病灶控制方面疗效明显,优于各药单药治疗.

Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis

Objective To evaluate the clinical therapeutic value of 188 Re HEDP combined with pamidronate in breast cancer with bone metastasis. Methods Forty eight patients with breast cancer with multi bone metastases were randomly divided into three groups:15 patients received 188 Re HEDP(group A), 15 patients received pamidronate(group B) and 18 patients were treated by 188 Re HEDP plus pamidronate (group C). Results The overall pain relief rate was 73.3%?80.0%?100.0% in groups A?B and C. The response rate of bone metastasis was 40.0%?33.3%?66.7% in groups A?B and C respectively. The therapeutic effect of group C was better than those of groups A and B ( P <0.05), without any significance in the difference ( P >0.05). Conclusion The therapeutic effect of 188 Re HEDP combined with pamidronate for breast cancer with bone metastasis is remarkable in bone pain relief and bone metastasis control, which is better than either 188 Re HEDP or pamidronate alone.